Premium
Raynaud phenomenon in three patients with acquired immune deficiency syndrome‐related kaposi sarcoma treated with bleomycin
Author(s) -
Von Gunten Charles F.,
Roth Ellen L.,
Von Roenn Jamie H.
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930915)72:6<2004::aid-cncr2820720635>3.0.co;2-5
Subject(s) - bleomycin , medicine , vinblastine , vincristine , sarcoma , doxorubicin , chemotherapy , kaposi's sarcoma , immune system , dermatology , pathology , immunology , cyclophosphamide , human herpesvirus
The authors report three cases of Raynaud phenomenon that developed during doxorubicin, bleomycin, and vincristine (ABV) therapy for acquired immune deficiency syndrome (AIDS)‐related Kaposi sarcoma. Although Raynaud phenomenon is well documented as a side effect of bleomycin, vinblastine, and cisplatin chemotherapy for germ cell neoplasms, it has not been widely documented in patients with AIDS.